European Biotechnology News 05/2013 - Free Excerpt: Biosimilars – up or down?

Nº 5 | Volume 12 | 2013 | 10.00 € | ISSN 1618-8276 | A 60711 |

European Biotechnology News Science & Industry

CENTRAL EUROPE

Roche dismantles Applied Science business unit NORTHERN EUROPE

Bavarian Nordic lands US$228m contract with US government Special

Biocapital – access to investments

T P R E C EE EX

FR

WESTERN EUROPE

Genticel bags investment for therapeutic HPV vaccine SOUTHERN EUROPE

Italy’s health ministry allows contested stem cell treatments Eastern EUROPE

Big Data’s role in a100m Polish drug development initiative

Biosimilars – up or down?

science & technology

Spanish scientists present list of DNA replication factors

Demanding Transfection. Easy Solution.

Focus your efforts on discovery. Efficiently transfect difficult cells, including more than 100 cancer cell lines using X-tremeGENE DNA Transfection Reagents.

Free sample and protocols at www.x-tremegene.roche.com

For life science research only.

Not for use in diagnostic procedures.

X-TREMEGENE is a trademark of Roche.

Roche Diagnostics GmbH Sandhofer StraĂ&#x;e 116 68305 Mannheim, Germany Š 2013 Roche Diagnostics.

All rights reserved.

N –º 5 | Volume 12 | 2013

Euro|Biotech|News

Intro

FREE EXCERPT

Editorial

The BRIDGE to a biobased economy in the EU

Dirk Carrez, Executive Director (a.i.), Biobased Industries Consortium (BIC), Brussels

I

Dirk Carrez is the Coordinator for BIC, an industry consortium that includes more than 40 European companies and organisations from the fields of technology, industry, agriculture and forestry that are preparing the Biobased Industries PPP. Carrez is also the Managing Director of Clever Consult, a consulting firm dedicated to different aspects of the bioeconomy. He is currently the Vice-Chair of the Biotechnology Committee at BIAC(Business and Industry Advisory Committee to the OECD) and the Vice-Chair of the OECD’s Task Force for Industrial Biotechnology.

n a post-petroleum society, biorefineries – along with the farmers and foresters who source raw materials – are at the heart of the economy. No matter how you define it, the concept remains the same: converting raw materials into useful products for society. Instead of fossil fuels, the biobased economy employs renewable resources and wastes to produce a series of products useful to society: biofuels, bioenergy, biochemicals, bioplastics and other biomaterials.

The potential social, economic and environmental benefits of this model are substantial across Europe. Farmers and foresters would play a pivotal role in enabling the biobased economy’s goals of delivering locally-sourced and produced materials, chemicals, fuels, food and feed. With sustainability at the heart of the biobased economy, growth could be decoupled from resource depletion and environmental degradation. That would in turn boost the EU’s ability to transition more rapidly to a low-carbon and resource­ efficient society, and it would further enable the EU to lead and compete in a global biobased economy market that is expected to reach the a200bn mark by 2020. The biobased economy is just the project to propel Europeans onto the path of reindustrial­isation and sustainable growth, and to reverse the current investment trend toward other regions of the world. It offers a road back to prosperity across all of the regions in the EU, and creates new jobs that will not simply disappear in the mid to long term. It will build on existing EU strengths and resources, embracing technological and scientific excellence, and creating new and novel partnerships between industries that have thus far remained unconnected. Supplementing food production, the conversion of bio­mass into bioproducts will likewise present a chance for the EU27 agricultural and forestry sectors to diversify revenues and revitalise rural areas.

For about a year now, industries across sectors have come together to discuss partnership opportunities with the EU. The resulting effort is called BRIDGE – a proposed “Biobased Industries Public-Private Partnership” in the form of a Joint Technology Initiative (JTI) known as the “Biobased and Renewables Industries for Development and Growth in Europe.”

BRIDGE is a €3.8bn commitment (EU: €1bn, Private sector: €2.8bn) over the 2014-2020 period, with a clear strategic research agenda that includes defined focus areas for demonstration projects and a set of flagship initiatives. Research institutes, academia and SMEs have been playing and will continue to play a crucial role in the PPP. The same goes for Member States, which will be instrumental in the process – particularly during the project deployment phase. The PPP might have been conceived in Brussels, but it will be implemented at national, regional and local levels across Europe. A Biobased Industries PPP in the form of a JTI is sending the right signals to invest in Europe, as well as to translate the EU’s R&D potential into new, innovative and sustainable biobased products and markets.

By the end of June 2013, the European Commission is scheduled to propose a (recovery) package of JTIs aimed at stimulating growth and jobs and improving the quality of life in Europe.

BRIDGE will be among these initiatives. The proposals are to be passed on to the European Parliament and the Council of the European Union for approval. The Biobased Industries Consortium (BIC) is calling on EU legislators to support the Commission JTI proposal for BRIDGE in order to unlock the biobased economy potential and trigger more sustainable growth in Europe. B

3

4

N –º 5 | Volume 12 | 2013

Euro|Biotech|News

CIRCUL ATION

FREE EXCERPT

European Biotechnology News is published in co-operation with the following organisations: European Biotechnology

CMYK

Net work

Europe: european-biotechnology.net

Blue: 100/15/0/35 Orange: 0/75/90/0

Germany: biodeutschland.org

Switzerland: swissbiotech.org

Council of European BioRegions

Europe: cebr.net

Europe: ebe-biopharma.org

Europe: eapb.org

Europe: europabio.org

Norway: biotekforum.no

Ireland: ibec.ie/ibia

Finland: finbio.net

Denmark: danskbiotek.dk

Sweden: swedenbio.com

The Netherlands: niaba.nl

Belgium: bio.be

Spain: asebio.com

France: france-biotech.org

Italy: assobiotec.it

Hungary: hungarianbiotech.org

EuroBiotechNews covers the biotechnology sector of the current 27 EU member states, Norway and Switzerland. If you would like to subscribe, please refer to Portugal: www.apbio.pt

www.eurobiotechnews.eu

N –º 5 | Volume 12 | 2013

5

Euro|Biotech|News

contents

FREE EXCERPT

Insight

Cover Story

EFSA rejects GM maize; MEPs delay transparency vote; Heard in Brussels 10 Bioeconomy SME initiative kicks off

12

EMA: pivotal trials shifting away from Europe

13

Study: bioplastics don’t affect use of arable land; IP Flash

14

Regulatory Affairs Update on clinical trials

16

Breaking news from the EMA

18

Economic Focus on newsflow and dividends

19

Stock markets

20

Perspectives

EU pushes the uptake of biosimilars

6

Faced with an uncertain regulatory background and the prospect of trials nearly as demanding as those faced by new clinical substances, many of the segment’s once enthusiastic pharma proponents have backed out of programmes or put projects on hold.

At the BIO congress in Chicago in late April, the European Commission presented its latest study on the sector – which makes a case that the positive aspects of biosimilars for both manufacturers and patients still far outweigh potential downsides.

BIO 2013: Sector grows in US and EU 43 Swiss Biotech remains strong

44

Interview: Lord Howe

46

Regional News

Services

Special

Partners & Associations

Biocapital Good capital access – for a few companies

33 34

Northern Europe

22

Central Europe

24

Making the right call in early-stage funding

Western Europe

26

Interview: Peter Homberg, Dentons

37

Southern Europe

28

India: Pharma innovations at grave risk

40

Eastern Europe

30

4

Biopeople News from Algeta ASA, Formycon GmbH, Scancell Holdings; Karolinska Development AB, Eyevensys, and Suppremol 47 Company index

48

Events What’s on in May-June 2013

49

Encore

50

Imprint European Biotechnology News is published monthly by: BIOCOM AG, Lützowstr. 33–36, D-10785 Berlin, Germany, Tel.: +49-30-264921-0, Fax: +49-30-264921-11, E-Mail: service@eurobiotechnews. eu; Internet: www.eurobiotechnews.eu, Publisher: Andreas Mietzsch, Editorial Team: Thomas Gabrielczyk (Managing Editor), Derrick Williams (Co-editor), Dr. Patrick Dieckhoff, Dr. Bernd Kaltwaßer, Dr. Martin Laqua; Advertising: Oliver Schnell, +49-30-2649-2145, Advertising USA: Avani Media, Inc. , Leslie Hallanan, Tel.: +1-415-331-2150 , Fax: +1-415-289-0402, E-Mail: leslie@avanimedia.com; Distribution: Marcus Laschke, +49-30-2649-2148; Printed at: Druckhaus Humburg, Bremen; Graphic Design: Michaela Reblin. European Biotechnology Science & Industry News is only regularly available through subscription at BIOCOM AG. Annual subscription fees: € 100.00, Students € 50.00 (subject to proof of enrolment). Prices include VAT, postage & packaging. Ordered subscriptions can be cancelled within 2 weeks directly at BIOCOM AG. The subscription is initially valid for one year. Subscriptions will be renewed automatically for one more year, respectively, unless they are cancelled at least 6 weeks before the date of expiry. Failures of delivery which BIOCOM AG is not responsible for do not entitle the subscriber to delivery or reimbursement of pre-paid fees. Seat of court is Berlin, Germany. As regards contents: individually named articles are published within the sole responsibility of their respective authors. All material published is protected by copyright. No article or part thereof may be reproduced in any way or processed, copied and proliferated by electronic means without the prior written consent of the publisher. Cover Photo: © 123rf.com ® BIOCOM is a registered trademark of BIOCOM AG, Berlin, Germany.

10

N –º 5 | Volume 12 | 2013

Euro|Biotech|News

INSIGHT EUROPE agri-Biotech

GMO rebound

Heard in Brussels M

A Brussels/Parma – For the first time since its inception, the European food safety watchdog EFSA has not recommended a GM crop for market. In mid-April, the experts from the agency’s GMO panel stressed that “the applicant failed to supply essential data to allow a full risk assessment to take place.” According to the EFSA, the “minimum standards for the design of field trials set out in the EFSA GMO Panel guidance document were not met” for Pioneer’s herbicide­-tolerant GM maize 98140, which prevented the panel from carrying out a comparative assessment of the compositional, agronomic and phenotypic characteristics and of potential risks to human and animal health. The maize has been genetically modified to express the GAT4621 and Zm-HRA proteins. GAT4621 is a glyphosate acetyltransferase (GAT) encoded by an optimised form of the gat4621 gene from Bacillus licheniformis that confers tolerance to glyphosate herbicides. The Zm-HRA protein is an acetolactate synthase (ALS) encoded by an optimised form of the endogenous ALS gene from Zea mays. It confers tolerance to ALS-inhibiting herb­icides such as chlorimuron and thifensulfuron.

B

Clinical Trials

Another delay A Strasbourg – The European Parliament’s ENVI Committee has postponed its vote on the draft clinical trials regulation until 29 May 2013. The Committee said it needed more time to discuss the over 700 compromise amendments that have been tabled on the European Commission’s draft legislation. In contrast to the Commission, MEPs want to publish full clinical study reports of approved medicines in the EU trials database instead of just a summary of trial results.

B

FREE EXCERPT

BIO: the synthesis of brilliance

Brussels – Greetings readers! The observant of you will note that I have strayed far from Brussels in my quest for knowledge – I was lucky enough to attend the BIO convention in Chicago in late April, and where better to listen out for sage advice? So what did I hear? Well, apart from the great parties (Belgian café at Buddy Guy’s Legends Club) and my failed chance to win a motorbike in the exhibition hall, I learned something very thought­-provoking from my favourite panel – a session focused on synthetic biology and its amazing potential.

I couldn’t possibly name the speakers, but it provided excellent insights into how much time large companies spend on processes that they would rather not have to do. If you run a large company producing novel crops, for example, you want to focus on the stuff you’re good at – producing the final crops themselves – rather than on time and money-consuming gene processing tasks. It’s not your speciality, nor is it your firm’s mission.

So you have a list of the technologies that you wish existed to make your route to products faster and more effective.

And this is where it got exciting; synthetic biology opens up tremendous market opportunities for smaller companies that can deliver advances in tech tools for processes that large product companies would rather avoid. One such SME (Ginkgo BioWorks) was represented on the speaker panel, and they fill that gap precisely. Their technology can produce organisms to customers’ exact specifications. It was an eye-opening glimpse into how bio­logy will soon be engineered from scratch, and why we will no longer just rely on tweaking existing genomes.

These companies are absolutely typical SMEs (Ginkgo was founded by PhD students). They had to beg, borrow and steal development funds to survive, and show the absolute necessity of genius. Only a

Claire Skentelbery, Secretary General of the European Biotechnology Network

bunch of fearless researchers would have founded this firm and invested in it for five years. I can’t see a large service provider investing the time, money and individual commitment required to bring this technology to fruition.

So the session reminded me of two things. The first is that behind every breakthrough product there is a whole pipeline of breakthrough technologies that enabled it. That’s the beauty of bio­ tech of course. Every new field brings multiple commercial opportunities for other new technologies. The second thing – which governments everywhere need to remember – is that SMEs drive applications for inventions, and you ignore them at your peril. Ginkgo’s fantastic platform was enabled and supported largely through grants. Although it saw little private investment, the firm looks set to help power the next generation of bio­-based products. The lesson? If you don’t support innovative SMEs, they can’t deliver.

I’m looking forward to BIO 2014 and hearing from a new wave of SMEs pursuing amazing technologies that will enable the next big product.

B

12

N –º 5 | Volume 12 | 2013

Euro|Biotech|News

INSIGHT EUROPE

M

Protesting an EU project

Brussels/Munich – GM opponents from the organisation Testbiotech have called on the European Commission to stop the EU project GRACE (GMO Risk Assessment and Communication of Evidence). At the end of April, they claimed the project was not transparent, and suggested that at least eight of its experts have conflicts of interest due to collaborations with agri­biotech companies. Testbiotech urged the Commission to stop the project, which is aimed at establishing new standards for GMO risk assessment, until potential conflict of interest issues have been solved. According to its head Jürgen Schiemann, the project will seek to test whether long-term feeding studies should be added to the current GMO risk assessment being carried out for EU food safety watchdog EFSA. At the launch of the project, Schiemann told EuroBiotechNews that he wanted to involve NGOs in setting up the testing criteria, but that some of them would be likely to reject that offer (see EuroBiotechNews 10/2012).

M

Taking aim at kinases

Brussels – Fuelled by a1.1m in EU money, six partners from industry and academia want to discover smallmolecule kinase-targeting drugs in the TAKTIC (Translational Kinase Tumour Inhibitor Discovery Consortium) venture. Together with academics from Italy, Israel, and France, the industry partners from SARomics Biostructures (Sweden), Prestwick Chemical (France) and ProQinase GmbH (Germany) are to create a new platform for lead compound discovery and test it on three different protein kinases. The consortium plans to licence the resulting IP to pharma partners.

EUropean union

Biotech SMEs snap up EU funds

© BBE

News

FREE EXCERPT

Bio Base Europe’s pilot plant in the Belgian city of Ghent.

A Brussels –Biotech SMEs involved in the bio-economy initiatives of five European countries are pooling their expertise in an EU project known as BioBaseNWE. The partners from the Bio Base Europe international non-profit organisation (BE), Ghent Bio-Energy Valley (BE), Bio Base Europe Training Center (NL), REWIN/Biobased Innovations (NL), German Cluster Industrielle Biotechnologie, the Galway­-based Competence Centre for Bio­ refining and Bioenergy (IRL) and the British National Non-Food Crops Centre (UK) said in April that they had secured a6.2m from the European Commission.

The overall goal of the three-year Bio Base NWE project is to drive growth and education in the bio-based economy in northwestern Europe. 50% of the project’s a12m overall budget has been granted by the INTERREG IVB North West Europe Programme. The other half comes from Agentschap Ondernemen (BE), Biobased delta (NL), Provincie Noord-Brabant (NL), Provincie Zeeland (NL), the National University of Ireland NUI Galway, Ireland’s Industrial Development Agency (IDA), Enterprise Ireland, and the National Develop­ment Plan Ireland. ”Bio-based products are a growing area of interest for SMEs working in the chemical industry, agro-industry, plastics, fuels, food, textile and the pharma industry,” stressed project

manager Lieve Hoflack. ”However, many SME’s find it difficult to bridge the gap between newly-developed research and the commercial market,” she added.

The network will provide SMEs with financial support for projects at the Bio Base Europe pilot plant in Ghent. The partnership will also develop and deliver programmes and tools for training skilled professionals for the bio-based industries.

About a2.9m – the lion’s share of the funding – is going to the facilities of the Bio Base Europe Pilot Plant, which grants access for SMEs to its a state-of-the-art facility through a special ‘coupon’ system. Within Bio Base NWE, SMEs can be granted a coupon worth a10,000 to carry out feasibility analyses, lab work or pilot tests there. According to Bio Base NWE, “this kind of support can be compared to seed capital, as it is intended for assessing the feasibility of an innovative biobased idea”.

Interreg IVB NWE describes the project as a network of bio-innovation agents that will be meeting every three months to discuss its work with SMEs and other stakeholders. They will jointly prepare products and activities for the entire project, which includes matchmaking workshops, needs assessment, innovation tools and round tables, training sessions and a summer school.

B

48

N –º 5 | Volume 12 | 2013

Euro|Biotech|News

Company And Advertiser Inde x 4SC AG (GER)… ………………………………… 34

A

Abbott GmbH & Co KG (GER)…………………… 47 Abbott Laboratories (USA)… …………………… 33 Abingworth LLP (UK)… ………………………… 26 Actelion AG (CH)… ……………………………… 19 Action Pharma A/S (DK)… ……………………… 33 Activartis Biotech GmbH (A)… ………………… 25 ADC Therapeutics Sarl (CH)……………………… 44 Addex Pharma (CH)… …………………………… 18 Aeris Capital AG (CH)… ………………………… 21 Affimed Therapeutics AG (GER)… ……………… 34 Agennix AG (GER/USA)… ……………………… 20 AiCuris GmbH & Co KG (GER)…………………… 33 Algeta ASA (N)… ………………………………… 47 Algiax Pharmaceuticals GmbH (GER)…………… 34 Alimera Sciences (F)……………………………… 19 Alkomohr Biotech Oy Ltd. (FIN)… ……………… 22 Allecra Therapeutics GmbH (GER)… …………… 25 Almirall S. A. (E)…………………………………… 18 Altia Oy (FIN)……………………………………… 22 Amgen Inc. (USA)……………………………… 8, 33 Amplidiag Oy (FIN)… …………………………… 20 Amsterdam Molecular Therapeutics (NL)… …… 36 Amundi Private Equity Funds (F)………………… 26 Apogenix AG (GER)… …………………………… 34 ASSOBIOTEC (IT)… ……………………………… 15 Associated British Food (UK)… ………………… 22 Astellas Pharma Europe B.V. (NL)… …………… 20 AstraZeneca AB (S/UK)……………………… 19, 33 Auris Medical (CH)… …………………………… 25 Avalon Ventures (USA)…………………………… 33 AyoxxA Biosystems GmbH (GER)… …………… 34

B

BASF SE (GER)… ………………………………… 47 Basilea Pharmaceutica (CH)…………………… 25, 33 Bavarian Nordic A/S (DK)……………………… 19, 22 Bayer AG (GER)………………………………… 14, 18 Bayer CropScience GmbH (GER)………………… 24 Berlin Partner GmbH (GER)………………………… 9 Biocartis SA (CH)… ……………………………… 44 BIOCOM AG (GER)… …………………………… 45 Biocon (IND)………………………………………… 8 Biohit Oyj (FIN)…………………………………… 29 BioInvent International AB (S)…………………… 23 BioMedInvest AG (CH)…………………………… 21 Blue Cross-Blue Shield (USA)… ………………… 33 Boehmert & Boehmert (GER)… ………………… 40 Boehringer Ingelheim (GER)… …………… 7, 8, 28 Bone Therapeutics (B)…………………………… 18 Borregaard Ind. Ltd (N)…………………………… 23 Brain AG (GER)… ………………………………34, 36 Bristol-Myers Squibb (USA)……………… 18, 22, 33 Brockmeyer Biopharma GmbH (GER)…………… 47

C

Caixa Capital Biomed (E)………………………… 29 Carbios SAS (F)…………………………………… 26 Cardio3 Biosciences (B)… ……………………… 18 CD-Venture GmbH (GER)………………………… 21 Celgene Europe Ltd. (UK)……………………… 20, 36 Cell2B (PT)………………………………………… 20 Celltrion (KR)………………………………………… 8 Cevec Pharma GmbH (GER)… ………………… 34 ChemAxon Ltd (HUN)… ………………………… 30 Chiroscience Group plc (UK)… ………………… 47 Chroma Therapeutics Ltd (UK)… ……………… 47 Cipla Ltd. (VRC)……………………………………… 8 Clavis Pharma ASA (N)…………………………… 47 Clever Consult (B)…………………………………… 3 Clinigen Group Ltd. (UK)… ……………………… 47 co.don AG (GER)… ……………………………… 34

Cobra Biologics (UK)……………………………… conogenetix biosciences GmbH (GER)… ………

Cooley Ventue (USA)… …………………………

Core Informatics (USA)……………………………

Corimmun GmbH (GER)… ………………………

Creabilis Therapeutics S.p.A. (LUX)………………

Curetis AG (GER)… ………………………………

Curevac GmbH (GER)… …………………………

17 34 36 30 36 27 21 34

D/E

Dermatools Biotech GmbH (GER)… …………… 34 Deutsche Messe AG (GER)… …………………… CP3 Distance a. Independent Studies Center (GER)… …… 13 DNA Electronics (UK)… ………………………… 24 Dompé Farmaceutici S.p.A. (I)…………………… 20 Edmond de Rothschild Investment (F)… …… 25, 26 Ernst & Young (UK)… …………………… 33, 43, 44 Eyevensys SA (F)… …………………………… 36, 47

F/G

F. Hoffmann - La Roche AG (CH)… 8, 18, 19, 21, 24 Forbion Capital Partners (NL)… ………………… 25 Forest Laboratories Inc. (USA)…………………… 18 Formycon AG (GER)……………………………… 47 Fujifilm Diosynth Biotechnologies (UK)… ……… 27 Galapagos NV (B)……………………………… 27, 33 Genewave SAS (F)… …………………………… 20 Genmab A/S (DK)………………………………23, 33 GenSight Biologics (F)… ………………………… 26 Genticel S.A. (F)… ……………………………… 26 Genzyme Corp. (USA)… ……………………… 20, 47 Gerresheimer AG (GER)… ……………………… 30 GlaxoSmithKline (UK)… ……………………… 20, 33 Grünecker Patent- und Rechtsanwälte (GER)…… 14

H

HBM Healthcare Investments (Cayman) (UK)… 25 HBM Partners AG (CH)…………………………… 21 Hexal AG (GER)…………………………………… 47 High-Tech Gründerfonds Managm. (GER)… … 19, 34 Horizon Discovery Ltd. (UK)……………………… 26 Hospira One 2 One Global Pharmaceutical (USA)… CP4

I/J

IBM Corp. (USA)… …………………………… 24, 30 Illumina Inc. (USA)………………………………… 24 IMS Health (UK)…………………………………… 6 Index Pharmaceuticals AB (S)… ………………… 18 Index Ventures (CH)……………………………… 26 ING BHF-BANK AG (GER)………………………… 47 Innovation Norway……………………………… 23 Janssen Pharmaceutica N.V. (B)… ……………… 28 Johnson & Johnson (USA)… …………………… 33 Jones Day (B)… ………………………………… 37

K/L

Karolinska Development AB (S)… ……………… 47 Kempen & Co (NL)… …………………………… 39 Keygene N.V. (NL)………………………………… 24 KfW Bankengruppe (GER)… …………………… 21 Knoll AG (GER)… ………………………………… 47 Life Science Austria LISA (A)……………………… 41 Life Sciences Partners (GER)… ………………… 21 Life Technologies GmbH (GER)… ………………… 7 Lonza AG (CH)… …………………………………… 8

M/N

Magforce Nanotechnologies AG (GER)… ………

Marinomed Biotechnologie GmbH (A)… ………

Medeva BV (NL)… ………………………………

Merck & Co. (USA)…………………………………

Merck Serono (CH)… ……………………………

Mercodia AB (S)……………………………………

Merrill Lynch (USA)… ……………………………

19 18 47 33 44 23 23

FREE EXCERPT

Minoryx Therapeutics S.L. (E)… ………………… 29 Mobidiag Oy (FIN)………………………………… 20 Mologen AG (GER)… ………………………… 18, 34 Nicox S.A. (F)……………………………………… 19 nova-Institut GmbH (GER)… …………………… 14 Novartis AG (CH)… ……………………………… 14 Novartis Venture Fund (CH)…………………… 26, 36 Novo Nordisk A/S (DK)…………………………23, 36

O/P

Orchid Biosciences Europe LTD (IND)… ……… 25 Orexo AB (S)… …………………………………… 19 Oxford Glycoscience (UK)… …………………… 47 Panmure Gordon (UK)…………………………… 20 Pfizer Ltd. (USA)………………………………… 8, 20 PharmaMar S.A. (E)… …………………………28, 29 Pharming Group N.V. (NL)… ………………… 19, 27 Pharmium Securities (F)… ……………………… 19 Phenex Pharmaceuticals AG (GER)……………… 34 Pioneer Hi-Bred International Inc. (USA)… …… 10 Prestwick Chemical (F)…………………………… 12 Priaxon AG (GER)… ……………………………… 25 Prime Therapeutics LLC (USA)…………………… 33 Probi AB (S)… …………………………………… 47 Probiodrug AG (GER)… ………………………… 34 Pronova Biopharma (N)… ……………………… 47 ProQinase GmbH (GER)… ……………………… 12 ProStrakan Group plc (UK)… …………………… 47 ProtAffin Biotechnologie AG (A)… ……………… 20 Proteros Biostructures GmbH (GER)… ………… 34

R/S

Raupach & Wollert-Elmendorff (GER)…………… 37 Roal Oy (FIN)……………………………………… 22 Roche Diagnostics GmbH (GER)…………… CP2, 37 Röhm GmbH & Co. KG (GER)… ………………… 22 Salans FMC SNR Denton (USA/GER)… ……… 35, 37 Sandoz Biopharmaceuticals (CH)… …………… 47 Sanofi SA (F)……………………………………… 30 Santaris Pharma A/S (DK)… …………………… 21 Santarus Inc. (USA)… ………………………… 19, 27 Santhera Pharmaceuticals (CH)… ……… 18, 26, 47 SARomics Biostructures (S)……………………… 12 SBH Diagnostics Inc. (CDN)……………………… 23 Scancell Holding plc. (UK)… …………………… 47 Serichim S.r.l. (IT)… ……………………………… 27 Silence Therapeutics AG (GER)… ……………… 34 Silicon Biosystems S.p.A. (IT)… ………………… 34 Sofinnova (F)……………………………………… 25 Subitec GmbH (GER)… ………………………… 34 Suppremol GmbH (GER)………………………… 47 Swedish Orphan Biovitrum AB (S)… …………… 47

T

t-cell Europe GmbH (GER)… …………………… 34 Tesco (UK)………………………………………… 27 Teva Pharmaceutical Industries Ltd. (IL)…………… 8 Theradiag SA (F)… ……………………………… 27 Thrombogenics (B)… …………………………… 19 Topo Target A/S (DK)… ………………………… 47 Torviscosa (IT)… ………………………………… 27

U/V

uniQure BV (NL)… ………………………………

Versant Ventures (USA)…………………………

ViroPharma Sprl (B)… ……………………………

Vossius und Partner (GER) … ……………………

W/Y/Z

36 26 20 15

Wellington Partners (GER)… …………………… 26 Wilex AG (GER)…………………………………… 34 Ylichron Srl (IT)… ………………………………… 29 Zeltia Group (E)…………………………… 11, 28, 29

EUROPEAN BIOTECHNICA AWARD 2013

: Save the date 3 7 October 201 Winner of the EUROPEAN BIOTECHNICA AWARD 2011: Unitectra AG

Don’t miss this year’s award presentation: 10th EUROPEAN BIOTECHNICA AWARD, given in recognition of a European biotech or life sciences organization with proven expertise and success in achieving “Integration of Biotechnology into the Industry” One of Europe’s most important biotechnology prizes, awarded by an international jury Monday, 7 October 2013, on the occasion of the BIOTECHNICA Opening Ceremony at the Hannover Exhibition Center (Hannover, Germany)

For detailed information simply go to: www.biotechnica.de/en/award

biotechnica.de

Parenteral Contract Manufacturing Service of Hospira

Our comfort zone is global parenteral manufacturing • Biologics • Highly Potent Drugs • Cytotoxics

• • • •

Betalactams Controlled Substances Sterile Compounding Single-Use Technology

• Lyophilization • Global Regulatory Services • QP Release

Zagreb, Croatia

Chennai, India

Discover your comfort zone at one2onecmo.com Get your custom report online or contact One 2 One. Call +1-224-212-2267 or +44 (0) 1926 835 554 or e-mail one2one@hospira.com

Your Parenteral Comfort Zone Parenteral Contract Manufacturing Service of Hospira

P11-3517A-Jan., 12